Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axonyx phenserine failed Phase III data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Axonyx continues to evaluate its development program for the acetylcholinesterase inhibitor phenserine in Alzheimer's disease following its Sept. 20 announcement of further negative Phase III results. Twelve-week data from two curtailed Phase III trials show no statistically significant benefit over placebo. The results follow a similar finding in an earlier Phase III trial, announced in February (1Pharmaceutical Approvals Monthly February 2005, p. 17). At that time, Axonyx had planned to recruit 900 patients total for the more recent studies. However, when the first Phase III study failed to show efficacy, "patient recruitment for these two ongoing Phase III trials was halted." A total of 255 patients were enrolled in the two more recent trials. Axonyx notes that its Phase IIb trial evaluating phenserine's ability to lower beta-amyloid precursor protein is ongoing...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS003059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel